Sandoz Reveals Aflibercept Program

Kicks Off Phase III Trials For Biosimilar Version Of Eylea

Sandoz has revealed late-stage clinical development plans for an aflibercept biosimilar, setting out details of a Phase III trial for the proposed Eylea rival.

Eye Scan Data
Sandoz is enrolling patients for an aflibercept trial • Source: Alamy

After recently expanding operations into new countries including Oman, Lebanon, Venezuela, Bolivia and Kosovo, Beximco Pharmaceuticals announced growth of 7.5% in export sales to BDT697.2m ($8.22m) for its financial third quarter ended 31 March 2021. The company’s export sales grew by 2.4% to BDT2.09bn for the full first nine months of its financial year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products